Nachrichten zur Eli Lilly & Co. Aktie

Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?

These two stocks both have market caps of more than $1 trillion, but Eli Lillys valuation is supported by strong…

Eli Lilly and J&J bounce on new data, as software stocks give up last weeks gains

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

3 ‘Vital Stories’ Films Had World Premieres At Tribeca Festival

The Tribeca and Eli Lilly "Vital Stories" program at the Tribeca Film Festival premiered short films Reconstructing Charlie, Run It…

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

The companys peers in the pharmaceutical industry should be worried.…

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

They are way more than just GLP-1 stocks.…

ATOS: Multiple Catalysts Converge in 2H26

By David Bautz, PhDNASDAQ: ATOSREAD THE FULL ATOS RESEARCH REPORTBusiness UpdateAtossa Therapeutics, Inc. (NASDAQ: ATOS) is approaching a potentially important…

Eli Lillys GLP-1 Pricing Problem Is Actually a Growth Opportunity

The stock continues to look unstoppable.…

Can Novo Nordisks GLP-1 Pill Momentum Offset LLYs Growing Edge?

NVOs GLP-1 pills offer fresh momentum, but Eli Lillys fast-growing injectable and oral therapies threaten to widen the competitive gap.…

Lilly gains access to market that could add millions of customers

Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is…

Novo Nordisk CEO defends lawsuit against Eli Lilly: Competition has to be fair

Novo Nordisk CEO defended the companys decision to sue rival Eli Lilly over its weight-loss drug advertising.…

Better Buy: Eli Lilly vs. Novo Nordisk

Novo Nordisk is playing catch-up in the GLP-1 race.…

UK green lights Lillys obesity pill

The British medicines ?regulator on Monday authorised Eli ?Lillys pill Foundayo for weight management and type 2 ?diabetes, ?becoming Europes…

Trotz gestrichener Milliarden: Eli-Lilly-Werk Alzey im Plan

ALZEY (dpa-AFX) - Der US-Pharmakonzern Eli Lilly will trotz der gestrichenen Milliardeninvestitionen die Produktionsstätte für Medikamente…

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Its not much of a rivalry yet.…

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate…

Eli Lillys Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?…

Eli Lilly: Fine Q2 2026 Results, But Alertness Required

…

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore…

Eli Lilly: GLP-1-Marktführer wächst mit Rekordquartal um 48 % - Aktie am Allzeithoch!

Das 2. Quartal überzeugt mit einem Umsatzwachstum von 48 %. Mounjaro und Zepbound liefern mit 14,9 Mrd. USD einen…

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as…

Were increasing our Eli Lilly price target after another beat-and-raise quarter

The strength of its GLP-1 business suggests the stock still has more room to run.…

ROUNDUP 2/Starke Gewichtssenker: US-Pharmakonzern Lilly hebt erneut Umsatzziel

(Kurs aktualisiert) INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt nach einem starken…

ROUNDUP/Starke Gewichtssenker: US-Pharmakonzern Lilly hebt erneut Umsatzziel

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt nach einem starken zweiten Quartal seine Prognose weiter…

Eli Lilly: Kapazitätsausbau und enorme Nachfrage nach GLP-1-Medikamenten prägen das 2. Quartal - Strategische Übernahmen sollen weiteres Wachstum sichern!

Eli Lilly profitiert massiv von der gigantischen Nachfrage nach Mounjaro und Zepbound, die Sättigungshormone nachahmen. Durch den Ausbau von…

KORREKTUR: US-Pharmakonzern Lilly hebt erneut Umsatzziel

(Korrigiert wird im letzten Satz die Erläuterung der Gewinnprognose. Diese wurde nur am oberen Ende gekürzt.) …

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of…

Market movers: Shopify, Uber, Eli Lilly, SolarEdge, CVS Health…

…

CVS blows past estimates, hikes guidance as insurance unit continues to improve

CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on…

WDH: Gewichtssenker florieren: US-Pharmakonzern Lilly hebt erneut Umsatzziel

(Tippfehler in der Überschrift behoben) INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt…

Gewichtssenker florieren: US-Pharmakonzern Lily hebt erneut Umsatzziel

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt nach einem starken zweiten Quartal seine Prognose weiter…

Jim Cramers top 10 things to watch in the stock market Wednesday

AMD and SpaceX are pulling back after earnings. But Eli Lilly is jumping after crushing estimates.…

Stocks making the biggest moves premarket: SpaceX, AMD, Eli Lilly, Disney & more

These are the stocks posting the largest moves premarket.…

Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%

Wall Street isnt convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly…

Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong

Eli Lilly and Co raised its full-year revenue forecast on Wednesday, banking on ?sustained demand for its blockbuster GLP-1 weight-loss…

Eli Lilly shares rise on revenue beat, raised outlook

Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results…

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1…

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start…

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

And it will likely be the first company in the sector to get there.…

Jim Cramer says one popular stock is meant to be owned, not traded

Most of what Cramer says on the "Mad Money" Lightning Round is fast and directional. Occasionally, he drops a framework…

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Watch Out, Eli Lilly and Novo Nordisk: Amgens Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and Its Coming for Your Patients

Will this pharma company become a new leader in the weight loss market?…

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnsons revenue has grown modestly while Eli Lillys revenue has nearly doubled in two years, narrowing a once-wide…

Goldman Sachs sees writing on the wall for Eli Lilly stock

Eli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on…

Eli Lilly, Dell Lead Five Stocks To Watch As Leadership Shifts

As AI-related stocks weaken, new leaders emerge.…

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity ?and diabetes drug…

Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people…

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of…

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Heres What That Means for Both Stocks.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.…

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Eli Lillys GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.…

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective…